Background The use of warfarin sodium for treating venous thromboembolism in patients
with cancer is associated with a significant risk of recurrence and bleeding. The use of low-
molecular-weight heparin sodium for secondary prevention of venous thromboembolism in
cancer patients may reduce the complication rate. Objective To determine whether a fixed
dose of subcutaneous low-molecular-weight heparin is superior to oral warfarin for the
secondary prophylaxis of venous thromboembolism in patients with cancer and venous …